July 16 (Reuters) - AstraZeneca ( AZN ) on Wednesday
said that its experimental drug anselamimab did not meet the
main goal of a late-stage study for the treatment of AL
amyloidosis, a rare condition that causes a buildup of protein
deposits in the body.